According to the latest status from February 2025, GlaxoSmithKline Pharmaceuticals paid a total of 44 INR per share in dividends within the last 12 months. With the current GlaxoSmithKline Pharmaceuticals price of 1,977.15 INR, this corresponds to a dividend yield of 2.23 %. A dividend is paid times per year.
| 2.23 % Dividend Yield | = |
|
A dividend is paid times per year. Last year, the payout months were July and December.
| Paydate | Dividend |
|---|---|
| 12/7/2024 | 12 |
| 7/1/2024 | 32 |
| 7/30/2023 | 32 |
| 8/7/2022 | 60 |
| 8/19/2021 | 30 |
| 8/17/2020 | 20 |
| 8/11/2019 | 20 |
| 8/13/2018 | 35 |
| 8/14/2017 | 30 |
| 8/15/2016 | 50 |
| 8/23/2015 | 62.5 |
| 5/3/2014 | 50 |
| 5/4/2013 | 50 |
| 4/29/2012 | 45 |
| 4/14/2011 | 40 |
| 4/10/2010 | 30 |
| 4/18/2009 | 18 |
| 5/2/2008 | 18 |
| 4/14/2007 | 14 |
| 4/24/2006 | 14 |
3 years
5 years
10 years
25 Years
Max
The dividend per year chart for GlaxoSmithKline Pharmaceuticals provides a comprehensive view of the annual dividends distributed to shareholders. Analyze the trend to understand the consistency and growth in dividend payouts over the years.
A consistent or increasing trend in dividends can indicate the company's profitability and financial health. Investors can use this data to identify GlaxoSmithKline Pharmaceuticals’s potential for long-term investment and income generation through dividends.
Incorporate the dividend data in evaluating GlaxoSmithKline Pharmaceuticals's overall performance. A thorough analysis, considering other financial aspects, will help in making informed investment decisions for optimal capital growth and income generation.
| Date | GlaxoSmithKline Pharmaceuticals Dividend |
|---|---|
| 2027e | 34.31 undefined |
| 2026e | 30.56 undefined |
| 2025e | 36.73 undefined |
| 2024 | 44 undefined |
| 2023 | 32 undefined |
| 2022 | 60 undefined |
| 2021 | 30 undefined |
| 2020 | 20 undefined |
| 2019 | 20 undefined |
| 2018 | 17.5 undefined |
| 2017 | 15 undefined |
| 2016 | 25 undefined |
| 2015 | 31.25 undefined |
| 2013 | 25 undefined |
| 2012 | 22.5 undefined |
| 2011 | 20 undefined |
| 2010 | 15 undefined |
| 2009 | 9 undefined |
| 2008 | 9 undefined |
| 2007 | 7 undefined |
| 2006 | 7 undefined |
| 2005 | 5.5 undefined |
| 2004 | 5 undefined |
| Dividend | Dividend (Estimate) | |
|---|---|---|
| 2004 | 5 INR | 0 INR |
| 2005 | 5.5 INR | 0 INR |
| 2006 | 7 INR | 0 INR |
| 2007 | 7 INR | 0 INR |
| 2008 | 9 INR | 0 INR |
| 2009 | 9 INR | 0 INR |
| 2010 | 15 INR | 0 INR |
| 2011 | 20 INR | 0 INR |
| 2012 | 22.5 INR | 0 INR |
| 2013 | 25 INR | 0 INR |
| 2015 | 31.25 INR | 0 INR |
| 2016 | 25 INR | 0 INR |
| 2017 | 15 INR | 0 INR |
| 2018 | 17.5 INR | 0 INR |
| 2019 | 20 INR | 0 INR |
| 2020 | 20 INR | 0 INR |
| 2021 | 30 INR | 0 INR |
| 2022 | 60 INR | 0 INR |
| 2023 | 32 INR | 0 INR |
| 2024 | 44 INR | 0 INR |
| 2025e | 0 INR | 36.73 INR |
| 2026e | 0 INR | 30.56 INR |
| 2027e | 0 INR | 34.31 INR |
GlaxoSmithKline Pharmaceuticals has been increasing the dividend for 2 years.
Over the past 10 years, GlaxoSmithKline Pharmaceuticals has increased it by an annual 5.816 %.
Over a five-year period, the distribution increased by 17.08%.
Analysts expect a Dividend Cut of -8.632% for the current fiscal year.
3 years
5 years
10 years
25 Years
Max
The yearly payout ratio for GlaxoSmithKline Pharmaceuticals represents the proportion of earnings paid out as dividends to shareholders. It is an indicator of the company's financial health and stability, illustrating how much profit is being returned to investors versus being reinvested back into the company.
A lower payout ratio for GlaxoSmithKline Pharmaceuticals could mean that the company is reinvesting more into its growth, whereas a higher ratio indicates more earnings are being distributed as dividends. Investors seeking regular income might prefer companies with a higher payout ratio, while those looking for growth may opt for companies with a lower ratio.
Evaluate GlaxoSmithKline Pharmaceuticals's payout ratio in conjunction with other financial metrics and performance indicators. A sustainable payout ratio, coupled with strong financial health, can indicate a reliable dividend payout. However, a very high ratio might suggest the company is not sufficiently reinvesting in its future growth.
| Date | GlaxoSmithKline Pharmaceuticals Payout ratio |
|---|---|
| 2027e | 134.61 % |
| 2026e | 148 % |
| 2025e | 125.96 % |
| 2024 | 129.88 % |
| 2023 | 188.15 % |
| 2022 | 59.84 % |
| 2021 | 141.64 % |
| 2020 | 362.98 % |
| 2019 | 75.9 % |
| 2018 | 84.34 % |
| 2017 | 75.3 % |
| 2016 | 112.36 % |
| 2015 | 110.89 % |
| 2013 | 87.72 % |
| 2012 | 67.69 % |
| 2011 | 78.86 % |
| 2010 | 45.22 % |
| 2009 | 29.95 % |
| 2008 | 25.74 % |
| 2007 | 21.61 % |
| 2006 | 21.47 % |
| 2005 | 18.66 % |
| 2004 | 25.92 % |
| Payout ratio | |
|---|---|
| 2004 | 25.92 % |
| 2005 | 18.66 % |
| 2006 | 21.47 % |
| 2007 | 21.61 % |
| 2008 | 25.74 % |
| 2009 | 29.95 % |
| 2010 | 45.22 % |
| 2011 | 78.86 % |
| 2012 | 67.69 % |
| 2013 | 87.72 % |
| 2015 | 110.89 % |
| 2016 | 112.36 % |
| 2017 | 75.3 % |
| 2018 | 84.34 % |
| 2019 | 75.9 % |
| 2020 | 362.98 % |
| 2021 | 141.64 % |
| 2022 | 59.84 % |
| 2023 | 188.15 % |
| 2024 | 129.88 % |
| 2025e | 125.96 % |
| 2026e | 148 % |
| 2027e | 134.61 % |
GlaxoSmithKline Pharmaceuticals’s dividends are a portion of the company’s profits distributed to shareholders. It is a critical indicator of the company’s financial health and attractiveness to investors. Dividends provide investors with a steady income stream, in addition to any profits that may come from selling the stock at a higher price than the purchase price.
Examining GlaxoSmithKline Pharmaceuticals's dividend distributions over the years can highlight the company’s profitability and stability. A consistent or increasing dividend payout can indicate a financially healthy company with predictable earnings, while fluctuations or reductions in dividends can suggest underlying financial or operational challenges.
GlaxoSmithKline Pharmaceuticals's dividend payments are an essential factor for income-focused investors. A robust dividend payout can enhance the stock’s appeal, offering regular income in addition to potential capital gains. It also can indicate the company's confidence in its future earnings, making it a significant consideration in investment decisions.
Changes in GlaxoSmithKline Pharmaceuticals’s dividends can result from shifts in the company’s earnings, financial policies, or reinvestment strategies. An increase in dividends often signals financial stability, while a decrease may indicate a need to conserve cash or reinvest profits to fuel growth, each scenario having different implications for investors.
Over the past 12 months, GlaxoSmithKline Pharmaceuticals paid a dividend of 44 INR . This corresponds to a dividend yield of about 2.23 %. For the coming 12 months, GlaxoSmithKline Pharmaceuticals is expected to pay a dividend of 30.56 INR.
The current dividend yield of GlaxoSmithKline Pharmaceuticals is 2.23 %.
GlaxoSmithKline Pharmaceuticals pays a quarterly dividend. This is distributed in the months of August, July, June, December.
GlaxoSmithKline Pharmaceuticals paid dividends every year for the past 23 years.
For the upcoming 12 months, dividends amounting to 30.56 INR are expected. This corresponds to a dividend yield of 1.55 %.
GlaxoSmithKline Pharmaceuticals is assigned to the 'Health' sector.
To receive the latest dividend of GlaxoSmithKline Pharmaceuticals from 11/28/2024 amounting to 12 INR, you needed to have the stock in your portfolio before the ex-date on 11/7/2024.
The last dividend was paid out on 11/28/2024.
In the year 2024, GlaxoSmithKline Pharmaceuticals distributed 32 INR as dividends.
The dividends of GlaxoSmithKline Pharmaceuticals are distributed in INR.
Our stock analysis for GlaxoSmithKline Pharmaceuticals Revenue stock includes important financial indicators such as revenue, profit, P/E ratio, P/S ratio, EBIT, as well as information on dividends. We also assess aspects such as stocks, market capitalization, debt, equity, and liabilities of GlaxoSmithKline Pharmaceuticals Revenue. If you are looking for more detailed information on these topics, we offer comprehensive analyses on our subpages.